Raymond James Financial Inc. Makes New $3.76 Million Investment in Tempus AI, Inc. (NASDAQ:TEM)

Raymond James Financial Inc. bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 111,288 shares of the company's stock, valued at approximately $3,757,000. Raymond James Financial Inc. owned approximately 0.07% of Tempus AI as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. increased its position in Tempus AI by 207.9% during the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after purchasing an additional 1,108 shares during the period. FNY Investment Advisers LLC purchased a new position in Tempus AI in the 4th quarter valued at about $67,000. IFP Advisors Inc purchased a new position in shares of Tempus AI during the fourth quarter valued at approximately $76,000. US Bancorp DE acquired a new stake in shares of Tempus AI during the fourth quarter worth $80,000. Finally, Stifel Financial Corp acquired a new stake in Tempus AI in the 3rd quarter worth about $218,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Trading Down 8.0 %

NASDAQ TEM traded down $4.14 during trading on Friday, reaching $47.83. 9,147,694 shares of the company traded hands, compared to its average volume of 5,242,580. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The stock's 50 day moving average price is $58.38 and its two-hundred day moving average price is $51.52.

Remove Ads

Insiders Place Their Bets

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the firm's stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the transaction, the insider now directly owns 15,218,365 shares of the company's stock, valued at approximately $534,164,611.50. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the sale, the chief executive officer now owns 4,895,589 shares in the company, valued at $287,615,853.75. This represents a 39.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,598,969 shares of company stock valued at $317,194,162.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Guggenheim restated a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. JPMorgan Chase & Co. lowered shares of Tempus AI from an "overweight" rating to a "neutral" rating and lifted their price target for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. William Blair reissued a "market perform" rating on shares of Tempus AI in a report on Tuesday, February 25th. Morgan Stanley upped their target price on shares of Tempus AI from $50.00 to $60.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Finally, Piper Sandler decreased their price target on Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.